Skip to main navigation
Disability accessibility tool
  • Contact Us
Neurocrine Biosciences logo
  • Your Health
    • Diseases & Conditions
    • Approved Medicines
    • TD Awareness
    • Investigational Therapies
  • Our Science
    • Approved Medicines
    • Pipeline
    • Clinical Studies
  • Our Company
    • About Us
    • Leadership
    • News & Media
    • Our Responsibility
    • DE&I
    • Grants & Sponsorships
  • Investors
    • Investor Overview
    • Stock Information
    • Financial Communications
    • Governance
    • Sustainability
    • Business Development
    • Webcasts & Presentations
  • Careers
    • Meet Our People
    • Work with Us
    • Explore Our Benefits
  • Your Health
    • Diseases & Conditions
    • Approved Medicines
    • TD Awareness
    • Investigational Therapies
  • Our Science
    • Approved Medicines
    • Pipeline
    • Clinical Studies
  • Our Company
    • About Us
    • Leadership
    • News & Media
    • Our Responsibility
    • DE&I
    • Grants & Sponsorships
  • Investors
    • Investor Overview
    • Stock Information
    • Financial Communications
    • Governance
    • Sustainability
    • Business Development
    • Webcasts & Presentations
  • Careers
    • Meet Our People
    • Work with Us
    • Explore Our Benefits
+
  • Investor Overview
  • Stock Information
    • Stock Quote
    • Shareholder Contacts
    • Analyst Coverage
  • Financial Communications
    • SEC Filings
    • Annual Meeting
    • Annual Reports
  • News Releases
  • Corporate Governance
  • Sustainability
  • Business Development
  • Webcasts & Presentations

Investor Overview

Latest News Releases

View All
6/2/23
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate
Read More
5/19/23
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
Read More
5/15/23
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society
Read More

2022 Annual Report

Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline.

Annual Reports

Stock Quote

(Common Stock)
  • Change
  • Volume
  • 52 Week High
  • 52 Week Low

03/31/23 11:42 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Latest Filings

Filing date Form Description Filing Group View
05/10/96 S-1/A

Amended Registration statement for face-amount certificate companies

Registration Statements
View HTML
0000898430-96-001702.pdf
0000898430-96-001702.rtf
0000898430-96-001702.xls
05/17/96 S-1/A

Amended Registration statement for face-amount certificate companies

Registration Statements
View HTML
0000898430-96-002108.pdf
0000898430-96-002108.rtf
0000898430-96-002108.xls
05/22/96 S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

Registration Statements
View HTML
0000898430-96-002214.pdf
0000898430-96-002214.rtf
0000898430-96-002214.xls

Data provided by Kaleidoscope.

Corporate Sustainability

Our ESG programs are aligned to our purpose, which we fulfill
through effective management of critical environmental, social, and
governance principles that are fundamental to our business.

2022 ESG Report

Email Alerts

Sign up to automatically receive Neurocrine Biosciences financial information by email

Sign Up Now

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contacts

 
Neurocrine logo
  • Diseases & Conditions
  • News & Media
  • Approved Medicines
  • Careers
  • Investigational Therapies
  • Leadership
  • Pipeline
  • Investors
  • Clinical Studies
  • Our Responsibility
Follow Us
Facebook logo
Linkedin logo
Twitter logo
©2022 Neurocrine Biosciences, Inc. All rights reserved.
 
  • Contact
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Accessibility
  • Sitemap